BioTelemetry, Inc. (NASDAQ:BEAT), LinkedIn Corp (NYSE:LNKD) and Spirit AeroSystems Holdings, Inc. (NYSE:SPR) are this Friday’s top gainers midday. On the losing end are Community Health Systems (NYSE:CYH), Biota Pharmaceuticals Inc (NASDAQ:BOTA) and Audience Inc (NASDAQ:ADNC).
LinkedIn Climbs on Positive Results
Wireless medical technology company BioTelemetry, Inc. (NASDAQ:BEAT) hit midday up +9.58% this Friday. The Q1 George Soros buy reported its second quarter financial results yesterday. Its price is up a slight +0.94% in the last month.
Maverick USA was down 3.3% for the second quarter, while Maverick Levered was down 2.1%. Maverick Long Enhanced was up 8%. Year to date, Maverick USA is up 31.8%, while Maverick Levered has gained 49.3%. Maverick Long Enhanced has returned 9.9% for the first six months of the year. Maverick Capital is a long/ short Read More
Corporate social network LinkedIn Corp (NYSE:LNKD) climbed +9.06% today, thanks to positive quarterly results and a revamped version of its Sales Navigator software. Billionaire hedge fund manager Ray Dalio upped his position in LNKD to 14,000 shares during the first quarter of the year.
Up +9.03% midday, Spirit AeroSystems Holdings, Inc. (NYSE:SPR) takes the last spot on today’s list of gainers. The Wichita-based company reported a Q2 profit this week and also lifted its full-year outlook for 2014. David Einhorn initiated a position in SPR in Q1 2013 and has likely made a gain on this one, given its price has climbed +39.82% in the past year.
Biota Pharmaceuticals Falls on Failed Drug Trial
Taking the top spot on today’s list of midday losers is Community Health Systems (NYSE:CYH), down -38.91%. It is a Q1 Farallon Capital pick.
Also having a rough Friday is Biota Pharmaceuticals Inc (NASDAQ:BOTA), its price falling -22.43% midday. The explanation: its flu treatment, one of its lead drugs, failed a mid-stage study. A new Q1 buy for George Soros, Biota has lost -42.72% year-to-date.
Audience Inc (NASDAQ:ADNC) fell -17.73% midday after Chardan Capital Markets downgraded its rating of the stock from buy to neutral, also lowering its price target to $9.00. Soros purchased 421,000 ADNC shares during the fourth quarter of 2013 and reduced his allocation slightly during the first quarter of this year. The stock is down -32.13% YTD.